Pyogenic granuloma association with isotretinoin treatment for acne

Simmons, Brian J.; Chen, Lucy; Hu, Shasa

doi:10.1111/ajd.12418

Cited by 15 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 It has also been reported after treatment with topical and/or systemic retinoids-such as isotretinoin-between two weeks and six months after the initiation of treatment. 3,4 Most cases reported in the literature are located in the periungual area (i.e. lateral and distal nail folds), although it can also affect the chest, back, face, scalp and, less frequently, the genital area, as in the present case.…”

Section: Commentsupporting

confidence: 49%

“…Alternatively, retinoids promote early stages of wound healing, cause the accumulation of mononuclear cells in the dermis and stimulate collagen synthesis, all of which may contribute to PG formation. 3,5 Different triggering factors have also been postulated, including local trauma, bacterial infections and skin fragility. 5,6 Such factors can lead to the formation of granulation tissue.…”

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

Pyogenic Granuloma in an Atypical Location Following Isotretinoin Treatment

Cuenca‐Barrales

Ródenas‐Herranz

Linares‐González

et al. 2018

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

show abstract

Section: Commentsupporting

confidence: 49%

Section: Commentmentioning

confidence: 99%

Pyogenic Granuloma in an Atypical Location Following Isotretinoin Treatment

Cuenca‐Barrales

Ródenas‐Herranz

Linares‐González

et al. 2018

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

show abstract

“…PG is commonly considered as a reactive inflammatory hyperproliferative vascular response to a variety of stimuli, such as infection, trauma, and female sex hormones 14 , but drug-induced PG is seldom seen. Only isolated case reports had described them in detail 15-18 . PG usually presents as a single, lobulated, pedunculated or sessile papule.…”

Section: Discussionmentioning

confidence: 99%

Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210

Chen

et al. 2019

Cancer Biology & Medicine

View full text Add to dashboard Cite

Objective SHR-1210 is a new and promising anti-PD-1 agent for solid tumors. During the phase I study of SHR-1210, we encountered a novel but prevalent immune-related dermatologic toxicity: reactive capillary hemangiomas (RCHs). Thus we tried to summarize the features of RCHs and estimate their relationship with tumor response. Methods This prospective observational study systematically enrolled 98 patients with advanced solid tumors from April 27th, 2016 to June 8th, 2017 in the context of the phase I clinical study of SHR-1210. This report focused on the skin toxicities. Patients underwent entire skin inspection every two weeks while taking medication. The clinical course of RCHs was recorded and their association with tumor response was estimated. The data cut-off date was November 15th, 2017. Results After a median follow-up of 242 (range, 29–567) days, RCHs were observed in 85.7% (84/98) of patients on cutaneous/mucosal surfaces; 84.5% (71/84) of the RCHs were evaluated as grade 1 adverse events. No grade 3 or 4 RCHs were observed. The time of onset of RCHs was dose dependent and shortest in the 400 mg-dose cohort ( P < 0.001). Spontaneous and complete regression of RCHs was observed both during and after treatment. The objective response rate of tumors for patients with RCHs was 28.9% (24/83). However, no responders were observed among the patients without RCHs. Conclusions RCHs were prevalent but manageable during treatment with SHR-1210. It might add to the expanding literature regarding immune-related dermatologic adverse events.

show abstract

“…PG has been associated with certain medications such as oral contraceptives, retinoids, gefitinib, cabecitabine, and afatinib [ 2 - 5 ]. Most tumours occur as solitary lesions, but multiple grouped or disseminated tumours have been described.…”

Section: Introductionmentioning

confidence: 99%

Pyogenic Granuloma – A Common Benign Vascular Tumor with Variable Clinical Presentation: New Findings and Treatment Options

Wollina¹,

Langner²,

França³

et al. 2017

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Pyogenic granuloma is a common benign vascular tumour occurring in all ages. Both skin and mucous membranes can be affected. Of pathogenetic importance are trauma, BRAF mutations and probably herpes virus type 1, Orf virus and/or human papilloma virus type 2. The tumour consists of capillary proliferations, venules and fibromyxoid stroma. The development of a lesion occurs in three stages and bleeding is a common symptom. The tumour can mimic various other vascular lesions, solid tumours, and soft tissue infections. In recent years, targeted tumour therapies have become the most common cause of drug-induced pyogenic granulomas. The backbone of treatment is surgical procedures including laser therapy. New developments in medical drug therapy include topical and systemic beta-adrenergic receptor antagonists timolol and propranolol. Drug therapy is an alternative for young children, ocular and periungual pyogenic granuloma.

show abstract

Pyogenic granuloma association with isotretinoin treatment for acne

Cited by 15 publications

References 4 publications

Pyogenic Granuloma in an Atypical Location Following Isotretinoin Treatment

Pyogenic Granuloma in an Atypical Location Following Isotretinoin Treatment

Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210

Pyogenic Granuloma – A Common Benign Vascular Tumor with Variable Clinical Presentation: New Findings and Treatment Options

Contact Info

Product

Resources

About